Interpretation of the World Health Organization key updates for endTB regimens to treat multidrug-resistant tuberculosis

doi:10.19983/j.issn.2096-8493.20250030

Abstract

Abstract:

Multidrug-resistant tuberculosis (MDR-TB) remains a major risk for human health. Recently, World Health Organization (WHO) has recommended new regimens for MDR-TB based on the endTB study. These regimens include drugs such as bedaquiline (Bdq), delamanid (Del), linezolid (Lzd), levofloxacin (Lfx) or moxifloxacin (Mfx), clofazimine (Cfz), and pyrazinamide (Z). Effective combinations include Bdq-Lzd-Mfx-Z, Bdq-Cfz-Lzd-Lfx-Z and Bqd-Del-Lzd-Lfx-Z. The new regimens expand the applicability of short-course regimens to MDR-TB patients with extensive lesions and are also suitable for special populations such as children, pregnant individuals, and people living with HIV. It is definitely an important event in the treatment of multidrug-resistant tuberculosis. The author briefly introduces research history, eligibility, and precautions of endTB study.

Key words: Tuberculosis, Drug resistance, Therapeutic uses, Consensus development conferences as topic

CLC Number:

Duan Hongfei. Interpretation of the World Health Organization key updates for endTB regimens to treat multidrug-resistant tuberculosis[J]. Journal of Tuberculosis and Lung Disease , 2025, 6(4): 361-364. doi: 10.19983/j.issn.2096-8493.20250030

References 13

[1]	舒薇, 刘宇红. 世界卫生组织《2023年全球结核病报告》解读. 结核与肺部疾病杂志, 2024, 5(1): 15-19. doi:10.19983/j.issn.2096-8493.2024006.
[2]	World Health organization. WHO consolidated guidelines on tuberculosis: Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization, 2022.
[3]	World Health Organization. Key updates to the treatment of drug-resistant tuberculosis: rapid communication. Geneva: World Health Organization, 2024.
[4]	Guglielmetti L, Ardizzoni E, Atger M, et al. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial. Trials, 2021, 22(1):651. doi:10.1186/s13063-021-05491-3. pmid: 34563240
[5]	Guglielmetti L, Khan U, Velásquez GE, et al. Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis. N Engl J Med, 2025, 392(5):468-482. doi:10.1056/NEJMoa2400327.
[6]	Goodall RL, Meredith SK, Nunn AJ, et al. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. Lancet, 2022, 400(10366):1858-1868. doi:10.1016/S0140-6736(22)02078-5. pmid: 36368336
[7]	Nyang’wa BT, Berry C, Kazounis E, et al. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med, 2022, 387(25):2331-2343. doi:10.1056/NEJMoa2117166.
[8]	World Health Organization. Management of drug-resistant tuberculosis in pregnant and peripartum people:a field guide. Boston: Sentinel Project for Pediatric Drug-Resistant Tuberculosis, 2022.
[9]	Xie YL, Chakravorty S, Armstrong DT, et al. Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis. N Engl J Med, 2017, 377(11):1043-1054. doi:10.1056/NEJMoa1614915.
[10]	Xia H, Zheng Y, Liu D, et al. Strong Increase in Moxifloxacin Resistance Rate among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China, 2007 to 2013. Microbiol Spectr, 2021, 9(3):e0040921. doi:10.1128/Spectrum.00409-21.
[11]	Farhat M, Cox H, Ghanem M, et al. Drug-resistant tuberculosis: a persistent global health concern. Nat Rev Microbiol, 2024, 22(10):617-635. doi:10.1038/s41579-024-01025-1.
[12]	Goig GA, Loiseau C, Maghradze N, et al. Transmission as a Key Driver of Resistance to the New Tuberculosis Drugs. N Engl J Med, 2025, 392(1):97-99. doi:10.1056/NEJMc2404644.
[13]	Van Rie A, Walker T, de Jong B, et al. Balancing access to BPaLM regimens and risk of resistance. Lancet Infect Dis, 2022, 22(10):1411-1412. doi:10.1016/S1473-3099(22)00543-6. pmid: 36007529

[1]	Tuberculosis Control Branch of Chinese Antituberculosis Association, Standardization Professional Branch of Chinese Antituberculosis Association, Elderly Tuberculosis Control Branch of Chinese Antituberculosis Association. Expert consensus on the application of Mycobacterium tuberculosis infection detection technologies [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(4): 365-381.
[2]	Tuberculosis Basic Professional Branch, Chinese Antituberculosis Association. Expert consensus on the standardization of broth microdilution method for drug susceptibility testing of Mycobacterium tuberculosis in China [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(4): 382-392.
[3]	Wu Yifei, Li Qingchun, Jia Qingjun, Huang Yinyan, Bai Xuexin, Cheng Qinglin. Identification and drug resistance analysis of non-tuberculous mycobacterial pulmonary disease pathogens in suburban areas of Hangzhou [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(4): 420-425.
[4]	Wei Yunxia, Wang Xin, Lin Hongxia, Li Yishuai. Study on the correlation between serum soluble PD-1 and the severity and prognosis of pulmonary tuberculosis patients in ICU [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(4): 426-431.
[5]	Liu Jing, Zhao Yuejuan. Comparison of ultrasound imaging characteristics between pulmonary tuberculosis and bacterial pneumonia in high-altitude environments [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(4): 432-435.
[6]	Liu Caifang, Zong Hua, Gao Yunfei, Yan Jin. The effect of different doses of esketamine on perioperative lung function and postoperative pulmonary complications in patients with pulmonary tuberculosis undergoing thoracoscopic surgery [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(4): 436-443.
[7]	Wei Daijue, Sun Jianjun, Chen Yan, Wang Shijun, Chang Yamei, Wei Nianhuan, Zhang Xin, Tong Chongxiang. Analysis of drug resistance of 2941 clinical isolates of Mycobacterium tuberculosis in Gansu Province [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(4): 444-448.
[8]	Zhang Wen, Cui Hongyan, Hou Wenjun. Epidemiological characteristics of tuberculosis and the establishment of seasonal autoregressive integrated moving average (SARIMA) model in Daxing district, Beijing, from 2015 to 2024 [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(4): 449-455.
[9]	Qi Dan, Wang Sheng, Liu Min, Gao Meiqin, Shi Feng, Li Bing, Bai Jun, Hao Ruixia, Wang Dong. Analysis of the etiological positive rate among pulmonary tuberculosis patients in designated tuberculosis hospitals in Ordos,Inner Mongolia Autonomous Region, 2015—2024 [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(4): 456-463.
[10]	Zou Jingjing, Cai Bin, Shi Jixia, Yang Li, Zhang Lumin. Summary of the best evidence for nutritional management in patients with acute exacerbation of chronic obstructive pulmonary disease [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(3): 261-268.
[11]	Nima Qucuo, Lyu Hengliang, Hu Fengmei, Zhang Wenyi, Xu Yuanyong. Spatiotemporal analysis on pulmonary tuberculosis in the Xizang Autonomous Region, 2010—2022 [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(3): 304-309.
[12]	Gu Yong, Mo Hui, Chen Hongmei, Lu Bo, Yi Chunmei, Gao Zhidong, Zhou Xiaofeng, Zhang Hongtai. Epidemiological trends of tuberculosis in Yuexi County, Liangshan Yi Autonomous Prefecture, Sichuan Province, 2005—2023 [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(3): 310-315.
[13]	Hou Kun, Wu Jinyi, Wang Xiaojun, Peng Peng. Influencing factors and risk prediction of delayed tuberculosis diagnosis in a tertiary hospital in Wuhan, China [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(3): 316-322.
[14]	Cao Hong, Deng Xiaolan, Li Zhen, He Yuqin, Wu Jinju, Lu Lunshan. Analysis of the detection and treatment outcomes of MTB/HIV co-infected patients in Hefei from 2014 to 2023 [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(3): 323-329.
[15]	Zhang Leijie, Li Pei, Wang Dan, Li Huiping, Zhu Ni. Influencing factors of diagnostic delay in pulmonary tuberculosis patients: a comparative study using three classification models [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(3): 335-342.